Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

Relapsed Follicular Lymphoma Clinical Trial

Official title:
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (Bortezomib) in Combination With Rituximab, Cyclophosphamide, and Prednisone With or Without Doxorubicin Followed by Rituximab Maintenance in Patients With Relapsed Follicular Lymphoma.

Status Completed

Clinical Trial Summary

This is a phase 2, two-arm, non-randomized, open-label, multicenter study evaluating the safety and efficacy of 2 VELCADE-containing regimens. Patients will be treated with either a combination of VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone (VELCADE-R-CAP) or a combination of VELCADE, rituximab, cyclophosphamide, and prednisone (VELCADE-R-CP) based on investigator preference. Following completion of the treatment period, patients will receive maintenance therapy with rituximab up to a maximum of 2 years.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00715208
Study type	Interventional
Source	Millennium Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	September 2008
Completion date	March 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05848765` - Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy	Phase 2
Completed	`NCT03806179` - Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL	Phase 1
Terminated	`NCT04699461` - Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma	Phase 2
Active, not recruiting	`NCT02956382` - Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05828589` - A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies	Phase 1
Withdrawn	`NCT05604417` - Zandelisib + Tazemetostat in R/R Follicular Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT01827605` - A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)	Phase 3
Active, not recruiting	`NCT04191187` - Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies	Phase 2